Alterations of expression and regulation of transforming growth factor β in human cancer prostate cell lines

Journal of Steroid Biochemistry and Molecular Biology

Volumn 82, Issue 4-5, 2002, Pages 297-304

  Blanchere M ^a   Saunier, E ^a   Mestayer, C ^b   Broshuis, M ^a   Mowszowicz, I ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Hormonal regulation; Prostate cancer; Stromal epithelial interactions; TGF

Indexed keywords

ANDROGEN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CANCER GROWTH; CELL ASSAY; CELL CULTURE; CELL LINE; CELL TYPE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FIBROBLAST; GENE EXPRESSION; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; STROMA;

BLOTTING, NORTHERN; CULTURE MEDIA, CONDITIONED; DIHYDROTESTOSTERONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR CELLS, CULTURED;

EID: 0036877421     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(02)00218-2     Document Type: Article

References (47)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics 1999. CA Cancer J. Clin. 49:1999;8-31.
2. Coffey D.S., Isaacs J.T. Control of prostate growth. Urology. 17:1981;17-24.
3. Henderson B.E., Ross R.K., Pike M.C. Toward the primary prevention of cancer. Science. 254:1991;1131-1138.
4. Blanchère M., Mestayer C., Saunier E., Broshuis M., Mowszowicz I. Transforming growth factor β in human prostate: its role in stromal-epithelial interactions in non cancerous cells in culture. Prostate. 46:2001;311-318.
5. Moses H.L., Yang E.Y., Pietenpol J.A. TGF-β stimulation and inhibition of cell proliferation. New mechanistic insights. Cell. 63:1990;245-247.
6. Peehl D.M., Sellers R.G. Basic FGF, EGF, and PDGF modify TGF-β-induction of smooth muscle cell phenotype in human prostatic stromal cells. Prostate. 35:1998;125-134.
7. Morton D.M., Barrack E.R. Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res. 55:1995;2596-2602.
8. Story M.T., Hopp K.A., Meier D.A. Regulation of basic fibroblast growth factor expression by transforming growth factor beta in cultured human prostate stromal cells. Prostate. 28:1996;219-226.
9. Lyons R.M., Keski-Oja J., Moses H.L. Proteolitic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J. Cell. Biol. 106:1988;1659-1665.
10. Truong L.D., Kadmon D., McCune B.K., Flanders K.C., Scardino P.T., Thompson T.T. Association of transforming growth factor-β1 with prostate cancer: an immunohistochemical study. Hum. Pathol. 24:1993;4-9.
11. Gerdes M., Larsen M., McBride L., Dang T.D., Lu B., Rowley D.R. Localization of transforming growth factor-β1 and type II receptor in developing normal human prostate and carcinoma tissues. J. Histochem. Cytochem. 46:1998;379-388.
12. Royuela M., De Miguel M.P., Bethencourt F.R., Sanchez-Chapado M., Fraile B., Paniagua R. Transforming growth factor β1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Growth Factors. 16:1998;101-110.
13. Perry K.T., Anthony C.T., Steiner M.S. Immunohistochemical localization of TGFβ1, TGFβ2, and TGFβ3 in normal and malignant human prostate. Prostate. 33:1997;133-140.
14. Guo Y., Jacobs S.C., Kyprianou N. Down regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in human prostate cancer. Int. J. Cancer. 71:1997;573-579.
15. Kim I.Y.I., Ahn H.J., Lang S., Oefelein M.G., Oyasu R., Kozlowski J.M., Lee C. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients. Clin. Cancer Res. 4:1998;1625-1630.
16. Kim I.Y.I., Ahn H.J., Zelner D.J., Shaw J.W., Lang S., Kato M., Oefelein M.G., Miyazono K., Nemeth J.A., Kozlowski J.M., Lee C. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 2:1996;1255-1261.
17. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., Heine U.I., Liotta L.A., Falanga V., Kehrl J.H.et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. U.S.A. 83:1986;4167-4171.
18. Ignotz R.A., Massague J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 261:1986;4337-4345.
19. Myrdol S.E., Twarzdzik D.R., Auersperg N. Cell-mediated co-action of transforming growth factors: incubation of type β with normal kidney cells produces a soluble activity that prolongs the ruffling response to type α J. Cell. Biol. 102:1986;1230-1234.
20. Wikström P., Westin P., Stattin P., Damber J.E., Bergh A. Early castration-induced upregulation of transforming growth factor β1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients. Prostate. 38:1999;268-277.
21. Itoh N., Patel U., Cupp A.S., Skinner M.K. Developmental and hormonal regulation of transforming growth factor-β1 (TGFβ1), -2, and -3 gene expression in isolated prostatic epithelial and stromal cells: epidermal growth factor and TGFβ interactions. Endocrinology. 139:1998;1378-1388.
22. Knabbe C., Klein H., Zugmaier G., Voigt K.D. Hormonal regulation of transforming growth factor β-2 expression in human prostate cancer. J. Steroid Biochem. Mol. Biol. 47:1993;137-142.
23. Kim I.Y.I., Kim J.H., Zelner D.J., Ahn H.J., Sensibar J.A., Lee C. Transforming growth factor-β1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology. 137:1996;991-999.
24. Scott-Lucia M., Sporn M.B., Roberts A.B., Stewart L.V., Danielpour D. The role of transforming growth factor-β1, -β2, and -β3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells. J. Cell. Physiol. 175:1998;184-192.
25. Cussenot O., Berthon P., Berger R., Mowszowicz I., Faille A., Hojman F., Teillac P., Le Duc A., Calvo F. Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. J. Urol. 143:1991;881-886.
26. Berthon P., Cussenot O., Hopwood L., Le Duc A., Maitland N.J. Functional expression of SV40 in normal prostatic epithelial and fibroblastic cells: differentiation pattern of non-tumorigenic cell lines. Int. J. Oncol. 6:1995;333-343.
27. Mowszowicz I., Kirchhoffer M.O., Kuttenn F., Mauvais-Jarvis P. Testosterone 5α-reductase activity of skin fibroblasts: increase with serial subcultures. Mol. Cell. Endocrinol. 17:1980;41-50.
28. Berthaut I., Portois M.C., Cussenot O., Mowszowicz I. Human prostatic cells in culture: different testosterone metabolic profile in epithelial cells and fibroblasts from normal or hyperplastic prostates. J. Steroid Biochem. Mol. Biol. 58:1996;235-242.
29. Berthaut I., Mestayer C., Portois M.C., Cussenot O., Mowszowicz I. Pharmacological and molecular evidence for the expression of the two steroid 5α-reductase isoenzymes in normal and hyperplastic human prostatic cells in culture. Prostate. 32:1997;155-163.
30. Blanchère M., Berthaut I., Portois M.C., Mestayer C., Mowszowicz I. Hormonal regulation of the androgen receptor expression in human prostatic cells in culture. J. Steroid Biochem. Mol. Biol. 66:1998;319-326.
31. Lawrence D.A., Pircher R., Jullien P. Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions. Biochem. Biophys. Res. Commun. 133:1985;1026-1034.
32. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the calorimetric estimation of deoxyribonucleic acid. Biochem. J. 62:1956;315-323.
33. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
34. Brown A.M.C., Jeltsch J.M., Roberts J.M., Chambon P. Activation of pS2 gene transcription is a primary response to estrogens in the human breast cancer cell line MCF-7. Proc. Natl. Acad. Sci. U.S.A. 81:1984;6344-6348.
35. Chang S.M., Chung L.W.K. Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen. Endocrinology. 125:1989;2719-2727.
36. Cunha G.R., Donjacour A.A., Cooke P.S., Mee S., Bigsby R.M., Higgins S.J., Sugimura Y. The endocrinology and developmental biology of the prostate. Endocrinol. Rev. 8:1987;338-362.
37. Wilding G., Zugmeier G., Knabbe C., Flanders K., Gelmann E. Differential effects of transforming growth factor β on human prostate cancer cells in vitro. Mol. Cell. Endocrinol. 62:1989;79-87.
38. Carruba G., Leake R.E., Rinaldi F., Chalmers D., Comito L., Sorci C., Pavone-Macaluso M., Castagnetta L.A.M. Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cells. Steroids. 59:1994;412-420.
39. Guo Y., Kyprianou N. Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGF-β1 sensitivity and signaling in human prostate cancer cells. Cell. Growth Differ. 9:1998;185-193.
40. Kim I.Y.I., Ahn H.J., Zelner D.J., Shaw J.W., Sensibar J.A., Kim J.H., Kato M., Lee C. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells. Cancer Res. 56:1999;44-48.
41. Chen R.H., Ebner R., Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science. 260:1991;1335-1338.
42. Veldscholte J., Ris-Stalpers C., Kuiper G.G.J.M., Jenster G., Berrevoets C., Claassen E., van Rooij H.C.J., Trapman J., Brinkmann A.O., Milder E. A mutation in the ligand binding domain of the androgen receptor of human LNCap cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173:1990;534-540.
43. Bruckheimer E.M., Kyprianou N. Dihydrotestosterone enhances transforming growth factor-β-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology. 142:2001;2419-2426.
44. Hiramatsu M., Maehara I., Ozaki M., Harada N., Orikasa S., Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate. 31:1997;118-124.
45. Kuiper G.G.J.M., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β Endocrinology. 138:1997;863-870.
46. Hering S., Surig D., Freystadt D., Schatz H., Pfeiffer A. Regulation of transforming growth factor β by sex steroid. Horm. Metab. Res. 27:1995;345-351.
47. Carruba G., Pfeffer U., Fecarotta E., Coviello D.A., D'Amato E., Lo Casto M., Vidali G., Castagnetta L. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res. 54:1993;1190-1193.